<DOC>
	<DOCNO>NCT00891735</DOCNO>
	<brief_summary>This Phase III , multicenter , randomize , double-masked , dose-comparison study efficacy safety ranibizumab injection administer intravitreally patient choroidal neovascularization ( CNV ) secondary age-related macular degeneration ( AMD ) . Results present first 12 month study .</brief_summary>
	<brief_title>A Study Ranibizumab Administered Monthly As-needed Basis Patients With Subfoveal Neovascular Age-related Macular Degeneration ( HARBOR )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>For sexually active woman childbearing potential , agreement use appropriate form contraception ( abstinence ) duration study . Ocular Inclusion Criteria ( Study Eye ) Best correct visual acuity ( BCVA ) , use Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart , 20/40âˆ’20/320 ( Snellen equivalent ) . Choroidal neovascularization ( CNV ) lesion classic CNV component , occult CNV , classic CNV component permissible . Total area lesion &lt; 12 disc area 30.48 mm^2 . History vitrectomy surgery , submacular surgery , surgical intervention agerelated macular degeneration ( AMD ) study eye . Prior treatment Visudyne ( R ) , externalbeam radiation therapy , transpupillary thermotherapy ( TTT ) study eye . Previous intravitreal drug delivery ( eg , intravitreal corticosteroid injection , antiangiogenic drug , device implantation ) study eye . Previous treatment participation clinical trial involve antiangiogenic drug ( Avastin ( R ) , anecortave acetate , protein kinase C inhibitor , etc ) , nonstudy eye within 3 month Day 0 ( first day treatment ) . The patient may receive Lucentis ( R ) Macugen ( R ) nonstudy eye within 7 day Day 0 . Treatment Visudyne ( R ) nonstudy eye &lt; 7 day precede Day 0 . Subretinal hemorrhage study eye involve center fovea , size hemorrhage either &gt; 50 % total area lesion &gt; 1 disc area ( 2.54 mm^2 ) size . Subfoveal fibrosis atrophy study eye . CNV either eye due cause , ocular histoplasmosis , trauma , pathologic myopia . Retinal pigment epithelial tear involve macula study eye . Any concurrent intraocular condition study eye ( eg , cataract diabetic retinopathy ) , opinion investigator , could either : Require medical surgical intervention 24month study period prevent treat visual loss might result condition ; allow progress untreated , could likely contribute loss least 2 Snellen equivalent line best correct visual acuity ( BCVA ) 24month study period . Uncontrolled blood pressure . Atrial fibrillation manage patient 's primary care physician cardiologist within 3 month screen visit . History stroke within last 3 month screen visit . History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication . Current treatment active systemic infection . Active malignancy . History allergy fluorescein , amenable treatment . Previous participation study investigational drug within 1 month precede Day 0 ( exclude vitamin mineral ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Lucentis</keyword>
	<keyword>AMD</keyword>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>Subfoveal neovascular age-related macular degeneration</keyword>
	<keyword>Wet AMD</keyword>
	<keyword>Macular degeneration</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>